ALLISON WADE: Open Payments
NPI 1356518872 · HAGERSTOWN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,352 in 57 payments from 12 companies in 2025. Trend: 2023 $907 · 2024 $835 · 2025 $1,352
Food & beverage: $1,352
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 13 | $447 |
| ABBVIE INC. | 22 | $421 |
| AstraZeneca Pharmaceuticals LP | 7 | $171 |
| Lundbeck LLC | 3 | $85 |
| PFIZER INC. | 3 | $56 |
| Amgen Inc. | 2 | $41 |
| Phathom Pharmaceuticals, Inc. | 2 | $28 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $23 |
| Abbott Laboratories | 1 | $22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $21 |
Products named: Ozempic, QULIPTA, VRAYLAR, AIRSUPRA, VYEPTI, UBRELVY, Rybelsus, NURTEC ODT.
Industry payments across MD — which companies pay providers there.
